{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:33:53Z","timestamp":1790746433433,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.revmed.2020.08.018","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T09:24:35Z","timestamp":1606123475000},"page":"101-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Les my\u00e9lofibroses"],"prefix":"10.1016","volume":"42","author":[{"given":"A.","family":"Genthon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7115-3248","authenticated-orcid":false,"given":"M.","family":"Killian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9781-7388","authenticated-orcid":false,"given":"P.","family":"Mertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cathebras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gimenez De Mestral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Guyotat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chalayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2020.08.018_bib0265","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.revmed.2020.08.018_bib0270","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.revmed.2020.08.018_bib0275","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.08.018_bib0280","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.emc.2014.04.014","article-title":"Myeloproliferative disorders","volume":"32","author":"Meier","year":"2014","journal-title":"Emerg Med Clin North Am"},{"key":"10.1016\/j.revmed.2020.08.018_bib0285","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.crad.2017.05.014","article-title":"Imaging features of myeloproliferative neoplasms","volume":"72","author":"Murphy","year":"2017","journal-title":"Clin Radiol"},{"key":"10.1016\/j.revmed.2020.08.018_bib0290","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.08.018_bib0295","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2014-12-618595","article-title":"Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells","volume":"126","author":"Lu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.08.018_bib0300","first-page":"89","article-title":"Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes","volume":"7","author":"Mughal","year":"2014","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.revmed.2020.08.018_bib0305","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/leu.2015.310","article-title":"Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis","volume":"30","author":"Verstovsek","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2020.08.018_bib0310","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1538-7836.2009.03686.x","article-title":"Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129\u00a0pregnancies","volume":"8","author":"Passamonti","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.revmed.2020.08.018_bib0315","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","article-title":"Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis","volume":"59","author":"Masarova","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.revmed.2020.08.018_bib0320","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3389\/fimmu.2019.01373","article-title":"Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms","volume":"10","author":"Marin Oyarz\u00fan","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.revmed.2020.08.018_bib0325","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: moving beyond JAK2\u00a0inhibition","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.revmed.2020.08.018_bib0330","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.08.018_bib0335","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF01451051","article-title":"Bone marrow findings in systemic lupus erythematosus patients with peripheral cytopenias","volume":"17","author":"Pereira","year":"1998","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.revmed.2020.08.018_bib0340","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2141.2007.06807.x","article-title":"Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres","volume":"139","author":"Kuter","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.08.018_bib0345","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00277-005-0042-8","article-title":"Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865\u00a0patients with chronic idiopathic myelofibrosis","volume":"85","author":"Thiele","year":"2006","journal-title":"Ann Hematol"},{"key":"10.1016\/j.revmed.2020.08.018_bib0350","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"39","article-title":"Polycythemia vera","author":"Thiele","year":"2017"},{"key":"10.1016\/j.revmed.2020.08.018_bib0355","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016\u00a0WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.08.018_bib0360","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1148\/radiol.2015150887","article-title":"Spleen Size Is Significantly Influenced by Body Height and Sex: Establishment of Normal Values for Spleen Size at US with a Cohort of 1200\u00a0Healthy Individuals","volume":"279","author":"Chow","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.revmed.2020.08.018_bib0365","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13244-019-0758-y","article-title":"Primary myelofibrosis: spectrum of imaging features and disease-related complications","volume":"10","author":"Oon","year":"2019","journal-title":"Insights Imaging"},{"issue":"12","key":"10.1016\/j.revmed.2020.08.018_bib0520","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/ajh.25230","article-title":"Primary myelofibrosis: 2019\u00a0update on diagnosis, risk-stratification and management","volume":"93","author":"Tefferi","year":"2018","journal-title":"American Journal of Hematology."},{"key":"10.1016\/j.revmed.2020.08.018_bib0370","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-018-0109-0","article-title":"Myelofibrosis Treatment Algorithm 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.revmed.2020.08.018_bib0375","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.15562","article-title":"What is pre-fibrotic myelofibrosis and how should it be managed in 2018?","volume":"183","author":"Curto-Garcia","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.08.018_bib0380","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081839","article-title":"Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options","volume":"20","author":"Iurlo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.revmed.2020.08.018_bib0385","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.08.018_bib0390","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/s-0034-1370794","article-title":"Thrombosis in myeloproliferative neoplasms","volume":"40","author":"Falanga","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.revmed.2020.08.018_bib0395","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2\u00a0exon 12\u00a0mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2020.08.018_bib0400","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016\u00a0revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.08.018_bib0405","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/sj.leu.2401553","article-title":"Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - a clinicopathological study","volume":"13","author":"Thiele","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2020.08.018_bib0410","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.hoc.2017.09.009","article-title":"TAFRO Syndrome","volume":"32","author":"Igawa","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.revmed.2020.08.018_bib0415","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ajh.10258","article-title":"Primary autoimmune myelofibrosis: Definition of a distinct clinicopathologic syndrome","volume":"72","author":"Pullarkat","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.revmed.2020.08.018_bib0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2193-1801-3-349","article-title":"Bone marrow fibrosis as a feature of systemic lupus erythematosus: a case report and literature review","volume":"3","author":"Chalayer","year":"2014","journal-title":"SpringerPlus"},{"key":"10.1016\/j.revmed.2020.08.018_bib0425","first-page":"701","article-title":"Bone marrow involvement in systemic lupus erythematosus","volume":"110","author":"Chalayer","year":"2017","journal-title":"QJM Mon J Assoc Physicians"},{"key":"10.1016\/j.revmed.2020.08.018_bib0430","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.08.018_bib0435","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.15450","article-title":"The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib","volume":"182","author":"Cris\u00e0","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2020.08.018_bib0440","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","article-title":"MIPSS70+ v2.0\u00a0predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen","volume":"3","author":"Ali","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.revmed.2020.08.018_bib0445","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2020.08.018_bib0450","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/10428194.2015.1046866","article-title":"Long-term results of prednisone treatment for the anemia of myelofibrosis","volume":"57","author":"Hern\u00e1ndez-Boluda","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.revmed.2020.08.018_bib0455","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/cncr.23505","article-title":"Risk factors for leukemic transformation in patients with primary myelofibrosis","volume":"112","author":"Huang","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2020.08.018_bib0460","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.leukres.2017.06.005","article-title":"Multicenter phase 2\u00a0study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis","volume":"60","author":"Gowin","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.revmed.2020.08.018_bib0465","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","article-title":"Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial","volume":"22","author":"Marchetti","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2020.08.018_bib0470","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2\u00a0dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.revmed.2020.08.018_bib0475","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3324\/haematol.2017.181297","article-title":"Benefits and pitfalls of pegylated interferon-\u03b12a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study","volume":"103","author":"Ianotto","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2020.08.018_bib0480","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223\u00a0patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.08.018_bib0485","first-page":"359","article-title":"Risks and benefits of splenectomy in myelofibrosis: an analysis of 39\u00a0cases","volume":"36","author":"Lafaye","year":"1994","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.1016\/j.revmed.2020.08.018_bib0490","first-page":"3630","article-title":"Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia","volume":"91","author":"Barosi","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2020.08.018_bib0495","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/bloodadvances.2018019661","article-title":"Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms","volume":"2","author":"Rampal","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.revmed.2020.08.018_bib0500","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2020.08.018_bib0505","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI82905","article-title":"Downregulation of GATA1\u00a0drives impaired hematopoiesis in primary myelofibrosis","volume":"127","author":"Gilles","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.revmed.2020.08.018_bib0510","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/15592294.2016.1265710","article-title":"Bromodomain inhibitors and cancer therapy: From structures to applications","volume":"12","author":"P\u00e9rez-Salvia","year":"2017","journal-title":"Epigenetics"},{"key":"10.1016\/j.revmed.2020.08.018_bib0515","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112267","article-title":"Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions","volume":"18","author":"Vasko","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.revmed.2020.08.018_bib2265","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/leu.2017.214","article-title":"The calreticulin (CALR) exon 9\u00a0mutations are promising targets for cancer immune therapy","volume":"32","author":"Holmstr\u00f6m","year":"2018","journal-title":"Leukemia"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320303672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320303672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:43:24Z","timestamp":1759337004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866320303672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0248866320303672"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2020.08.018","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les my\u00e9lofibroses","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2020.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}